1
|
Asafu-Adjaye EB, Wong SK, Arnason J, Betz J, Breakell K, Chen JX, Fitzloff J, Fong HHS, Kim CS, Kwan SY, Leung HW, Li GQ, Lin RC, Luo GA, Nicolidakis H, Park H, Suen E, Wang XR, Wang ZT, Wen KC, Yeung HW. Determination of Ginsenosides (Ginseng Saponins) in Dry Root Powder from Panax ginseng, Panax quinquefolius, and Selected Commercial Products by Liquid Chromatography: Interlaboratory Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/86.6.1112] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Twelve collaborating laboratories assayed 4 products, namely, Panax ginseng, Panax quinquefolius, and 2 ginseng products, for 6 ginsenosides: Rb1, Rb2, Rc, Rd, Re, andRg1. Collaborators also received a negative control for the recovery study. Pure ginsenosides were provided as reference standards for the liquid chromatography (LC) analysis and the system suitability tests. The LC analyses were performed on the methanol extract using UV detection at 203 nm. For P. ginseng, individual ginsenosides were consistent in their means; repeatability standard deviations (RSDr)rangedfrom4.17to5.09% and reproducibility standard deviations (RSDR) ranged from 7.27 to 11.3%. For P. quinquefolius, the Rb1 and Rb2 ginsenosides were higher and lower in concentration than P. ginseng, with RSDr values of 3.44 and 6.60% and RSDR values of 5.91 and 12.6% respectively, and other analytes at intermediate precisions. For ginseng commercial products, RSDr values ranged from 3.39 to 8.12%, andRSDR values ranged from 7.65 to 16.5%. A recovery study was also conducted for 3 ginsenosides: Rg1, Re, andRb1. The average recoveries were 99.9, 96.2, and 92.3%, respectively. The method is not applicable for the determination of Rg1 and Re in ginseng product at levels <300 mg/kg.
Collapse
Affiliation(s)
- Ebenezer B Asafu-Adjaye
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Product Quality Research Laboratory, HFD-941, NLRC Ste 2400, Rockville, MD 20857
| | - Siu Kay Wong
- Hong Kong Government Laboratory, Homantin Government Offices, 88 Chung Hau St, Hong Kong
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Topp M, Arnason J, Advani R, Brown J, Allan J, Ansell S, O'Brien S, Chavez J, Duell J, Rosenwald A, Charnas R, Ambati S, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Murphy A, Yancopoulos G, Lowy I, Sternberg D, Bannerji R. CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL). Hematol Oncol 2019. [DOI: 10.1002/hon.58_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.S. Topp
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - J. Arnason
- Hematology/Oncology Division; Beth Israel Deaconess Medical Center; Boston United States
| | - R. Advani
- Department of Medicine; Stanford University; Stanford United States
| | - J.R. Brown
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston United States
| | - J. Allan
- Division of Hematology and Medical Oncology; Weill Cornell Medicine; New York United States
| | - S. Ansell
- Department of Internal Medicine; Mayo Clinic; Rochester United States
| | - S. O'Brien
- Division of Hematology/Oncology; University of California; Irvine United States
| | - J. Chavez
- Department of Oncologic Sciences; Moffitt Cancer Center; Tampa United States
| | - J. Duell
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - R. Charnas
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S.R. Ambati
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - L. Adriaens
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - M. Ufkin
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - M. Zhu
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - J. Li
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - P. Gasparini
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - V. Jankovic
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - N. Fiaschi
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - W. Zhang
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S. Hamon
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G. Thurston
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - A.J. Murphy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G.D. Yancopoulos
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - I. Lowy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - D. Sternberg
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - R. Bannerji
- Section of Hematologic Malignancies; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| |
Collapse
|
3
|
Gunnarsson S, Johansson M, Gústavsson A, Arnason T, Arnason J, Smáradóttir H, Björnsson BT, Thorarensen H, Imsland AK. Effects of short-day treatment on long-term growth performance and maturation of farmed Arctic charr Salvelinus alpinus reared in brackish water. J Fish Biol 2014; 85:1211-1226. [PMID: 25263189 DOI: 10.1111/jfb.12524] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2014] [Accepted: 08/07/2014] [Indexed: 06/03/2023]
Abstract
The effects of a 6 week short-day photoperiod followed by continuous light, applied during the juvenile phase of Arctic charr Salvelinus alpinus in fresh water on smoltification and on the long-term growth and maturity following transfer to brackish water (BW) (constant salinity of either 17 and 27 or increasing salinity in steps from 17 to 27) were investigated. Prior to salinity transfer, the juveniles were either reared at continuous light (C group) or reared for 6 weeks on a short day (8L:16D, S group) followed by continuous light (24L:0D). Increased salinity had negative effect on growth, with female fish reared at 17 salinity weighing 19 and 27% more than the salinity-step group (17-27) and the 27 salinity group, respectively. The stepwise acclimation to salinity had limited advantage in terms of growth rate. Short photoperiod for 6 weeks (November to January) followed by continuous light improved growth, but not seawater (SW) tolerance. Gill Na(+) , K(+) -ATPase activity and plasma Na(+) levels changed with time, indicating some variation in osmoregulatory capacity during the experimental period. Overall, there appear to be interactive effects on maturation from applying short-day photoperiod followed by rearing at higher salinities. Plasma leptin varied with time and may be linked to stress caused by the observed variations in osmoregulatory ability. It is concluded that changes in growth rates observed in this study are mainly related to rearing salinity with higher growth rates at lower salinities. Short-day photoperiod has some growth-inducing effects but did not improve SW tolerance. Farmers of S. alpinus using BW for land-based rearing should keep salinity at moderate and stable levels according to these results to obtain best growth.
Collapse
Affiliation(s)
- S Gunnarsson
- Akvaplan-niva Iceland Office, Akralind 4, 201 Kópavogur, Iceland; Department of Biology, University of Bergen, High Technology Centre, 5020 Bergen, Norway
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Necyk C, Boon H, Foster B, Jaeger W, LeGatt D, Cembrowski G, Murty M, Vu D, Leitch R, Tsuyuki R, Barnes J, Charrois T, Arnason J, Ware M, Rosychuk R, Vohra S. P04.51. Study of natural health product adverse reactions (SONAR): active surveillance in community pharmacies. BMC Complement Altern Med 2012. [PMCID: PMC3373583 DOI: 10.1186/1472-6882-12-s1-p321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Glotzbecker B, Mills H, Rosenblatt J, Joyce R, Levine J, Tzachanis D, Stevenson M, Attar E, Ballen K, Chen YB, Boussiotis V, Zwicker J, Luptakova K, Arnason J, Bonhoff J, Delaney C, Conway K, Giallombardo N, Mortellite J, Fitzgerald D, O'Brien S, McMahon C, Vasir B, Stroopinsky D, Spitzer T, Avigan D. Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Rosenblatt J, Stone R, Avivi I, Uhl L, Neuberg D, Joyce R, Tzachanis D, Levine J, Boussiotis V, Zwicker J, Arnason J, Luptakova K, Steesma D, DeAngelo D, Galinsky I, Vasir B, Somaiya P, Mills H, Yuan E, Bonhoff J, Delaney C, Drummy N, Nicholson L, Stroopinsky D, Held V, Katz T, Rowe J, Kufe D, Avigan D. Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
|
8
|
Baribaud F, Pöhlmann S, Sparwasser T, Kimata MT, Choi YK, Haggarty BS, Ahmad N, Macfarlan T, Edwards TG, Leslie GJ, Arnason J, Reinhart TA, Kimata JT, Littman DR, Hoxie JA, Doms RW. Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J Virol 2001; 75:10281-9. [PMID: 11581396 PMCID: PMC114602 DOI: 10.1128/jvi.75.21.10281-10289.2001] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
DC-SIGN, a type II membrane protein with a C-type lectin binding domain that is highly expressed on mucosal dendritic cells (DCs) and certain macrophages in vivo, binds to ICAM-3, ICAM-2, and human and simian immunodeficiency viruses (HIV and SIV). Virus captured by DC-SIGN can be presented to T cells, resulting in efficient virus infection, perhaps representing a mechanism by which virus can be ferried via normal DC trafficking from mucosal tissues to lymphoid organs in vivo. To develop reagents needed to characterize the expression and in vivo functions of DC-SIGN, we cloned, expressed, and analyzed rhesus macaque, pigtailed macaque, and murine DC-SIGN and made a panel of monoclonal antibodies (MAbs) to human DC-SIGN. Rhesus and pigtailed macaque DC-SIGN proteins were highly similar to human DC-SIGN and bound and transmitted HIV type 1 (HIV-1), HIV-2, and SIV to receptor-positive cells. In contrast, while competent to bind virus, murine DC-SIGN did not transmit virus to receptor-positive cells under the conditions tested. Thus, mere binding of virus to a C-type lectin does not necessarily mean that transmission will occur. The murine and macaque DC-SIGN molecules all bound ICAM-3. We mapped the determinants recognized by a panel of 16 MAbs to the repeat region, the lectin binding domain, and the extreme C terminus of DC-SIGN. One MAb was specific for DC-SIGN, failing to cross-react with DC-SIGNR. Most MAbs cross-reacted with rhesus and pigtailed macaque DC-SIGN, although none recognized murine DC-SIGN. Fifteen of the MAbs recognized DC-SIGN on DCs, with MAbs to the repeat region generally reacting most strongly. We conclude that rhesus and pigtailed macaque DC-SIGN proteins are structurally and functionally similar to human DC-SIGN and that the reagents that we have developed will make it possible to study the expression and function of this molecule in vivo.
Collapse
Affiliation(s)
- F Baribaud
- Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
OBJECTIVES To review the literature about common autoantibodies produced in association with viral infection. METHODS Medline review of the medical literature published in English. RESULTS Common viral infections are often associated with low-titer, polyspecific autoantibodies. However, high-titer antinuclear antibodies, double-stranded DNA antibodies, anticardiolipin antibodies, and other subtype antibodies may be found. Hepatitis C and B virus, human immunodeficiency virus, and parvovirus B19 appear to be associated with autoantibodies more commonly than other viruses. CONCLUSIONS Transient autoantibodies resulting from viral infections are not uncommon. Clinical and laboratory follow-up over time will help distinguish between connective tissue disease and self-limited illness.
Collapse
Affiliation(s)
- K E Hansen
- University of Wisconsin Hospital and Clinics, Madison 53792, USA
| | | | | |
Collapse
|